The new drug, called EC905 is a treatment used to tackle the symptoms of benign prostatic hyperplasia (BPH). The drug combines two of the pharmaceutical companies highest selling products – Harnal and Vesicare.
Traditionally, patients suffering with BPH have had to take a combination of different drugs. So, it is hoped that the approval of EC905 will help make their lives a little easier by elevating the pill burden.
Astellas are filing for EU approval based on the results of their phase III NEPTUNE study which found that the drug improved lower urinary tract infections in men aged over 45.